Mark Sulkowski, MD is a Professor of Medicine at Johns Hopkins University. The advent of highly effective treatments for Hepatitis C represents remarkable scientific achievement marked by many important milestones including the recognition of non-A, non-B Hepatitis (1975); identification of the virus (1989); development of in vitro systems to study the virus and potential antiviral[…]
The other important component of the U.S. Hepatitis C epidemic is smaller in absolute numbers but is the major source of new Hepatitis C infections: infections associated with the opioid epidemic, injection drug use, and the sharing of needles and other drug injection equipment.
How is a curable disease still wreaking havoc on public health in this country? Why can’t we just treat and cure these people and make Hepatitis C a rare disease? The answers to these questions are complex, but those who work on Hepatitis C issues can agree on a key obstacle in achieving our goal of decreased Hepatitis C prevalence: we don’t invest enough in the prevention of Hepatitis C, or in the treatment of the disease.
New data featured on HepVu.org estimate about 3.9 million non-institutionalized people have had past or current Hepatitis C virus (HCV), and in 2010 an estimated 2.7 million had chronic HCV infections.
The CDC estimates that between 850,000 and 2.2 million people have chronic HBV in the U.S., and approximately 19,200 new HBV infections occur each year. Share our infographics below to help your community stay informed about Hepatitis B. Download the full Hepatitis B Infographic. View the Hepatitis C infographics.
The CDC estimates that there are more than 3.9 million individuals in the U.S. living with past or current Hepatitis C infection, and approximately 17,000 new Hepatitis C infections occur each year. Share these infographics on your social networks to keep your community informed about Hepatitis C. Download the full Hepatitis C infographic. View the Hepatitis[…]
Today, we are proud to announce the launch of HepVu.org, a new interactive website that visualizes the first standardized state-level estimates of Hepatitis C prevalence across the United States. HepVu’s development was guided by a group of viral hepatitis experts, and the website is presented by the Rollins Schools of Public Health at Emory University[…]
Chari Cohen is Director of Public Health for the Hepatitis B Foundation. She conducts programs and research focusing on reducing health disparities related to Hepatitis B infection and liver cancer. Dr. Cohen is director of Hep B United Philadelphia, and Chair of the Coalition Against Hepatitis for People of African Origin. She also helps lead[…]
Dr. Eli Rosenberg is an Assistant Professor at Emory University’s Rollins School of Public Health in the Department of Epidemiology. He is also the Principal Investigator for Emory University’s Coalition for Applied Modeling for Prevention (CAMP). Viral hepatitis is a burgeoning public health epidemic. Since 2012, deaths associated with Hepatitis C in the U.S. have[…]